Losers: AN2 Therapeutics (ANTX) -70% after pause on pivotal trial. Larimar Therapeutics (LRMR) -38% reports positive top-line data from phase 2 dose exploration study from 25 mg and 50 mg Cohorts of ...
Source LinkLosers: AN2 Therapeutics (ANTX) -70% after pause on pivotal trial. Larimar Therapeutics (LRMR) -38% reports positive top-line data from phase 2 dose exploration study from 25 mg and 50 mg Cohorts of ...
Source Link
Comments